BRAF and keratoacanthoma: Keratoacanthoma and Squamous Cell Carcinoma of the Skin: A distinct feature of the BRAF inhibitors is their ability to induce secondary cutaneous malignancies, such as keratoacanthomas (KAs) and cSCCs.